fashion -WSS

fashion

author：knowledge 2025-10-02 17:27:33 - browse：926

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Asbestos, a deadly carcinogen, banned by EPA

Wikipedia

knowledge

WSS

Intermittent fasting comes with a heart risk? Not so fast

Neuroscience’s long legacy of racism

Doctors' information doesn't help them choose wisely when sick

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Medicare threatens to cut off funding for HCA's Mission hospital

Doctors' information doesn't help them choose wisely when sick

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

explore

How one medical school became remarkably diverse

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Supreme Court strikes down use of affirmative action

Biogen Alzheimer’s drug launch off to slow start

In Memoriam: Notable people who died in 2023

Physicians and social media: If you see something, say something?

Walensky prepares to leave CDC — and Congress — behind

KalVista pill reduced swelling 'attacks' caused by genetic disease

Peter Hotez and the public health issue of online harassment

Orchard's therapy for neuron disease in children wins FDA approval

leisure time

UnitedHealth increases loan offers after Change Healthcare outage

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

PhRMA lawsuit over Medicare drug price negotiation tossed

U.K. researchers warn about biases in medical devices, algorithms

Medicare Advantage proposed rates disappoint insurers

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Wikipedia

knowledge

explore

knowledge